Openfund

CORDIS · DIOPTRA

EARLY DYNAMIC SCREENING FOR COLORECTAL CANCER VIA NOVEL PROTEIN BIOMARKERS REFLECTING BIOLOGICAL INITIATION MECHANISMS

Код
DIOPTRA
Програма
HORIZON
Процедура
HORIZON-MISS-2021-CANCER-02-01
Статус
SIGNED
Период
01.01.2023 – 31.12.2026
Обща стойност (целият консорциум)13 647 601 €
Принос на ЕС (целият консорциум)13 646 550 €
Принос на ЕС за българските участници54 688 €

Официални данни · CORDIS · синхронизирано 17.10.2026 10:16 · официален запис

Участници

ОрганизацииРоляДържаваБезвъзмездна помощ
EREVNITIKO PANEPISTIMIAKO INSTITOUTO SYSTIMATON EPIKOINONION KAI YPOLOGISTONкоординаторEL942 500 €
PROTAVIO MONOPROSOPI E.P.EучастникEL4 648 750 €
CENTRE HOSPITALIER UNIVERSITAIRE DE LIEGEучастникBE508 750 €
PANEPISTIMIO IOANNINONучастникEL500 875 €
GENIKO ANTIKARKINIKO OGKOLOGIKO NOSOKOMEIO ATHINON O AGIOS SAVVASучастникEL491 875 €
REGION SYDDANMARKучастникDK477 210 €
ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINONучастникEL474 000 €
FUNDACION BURGOS POR LA INVESTIGACION DE LA SALUDучастникES452 500 €
Univerzitetni klinicni center MariborучастникSI445 000 €
LINAC-PET SCAN OPCO LIMITEDучастникCY418 750 €
KOMITEEN FOR SUNDHEDSOPLYSNINGучастникDK389 250 €
EUROPEAN HOSPITAL AND HEALTHCARE FEDERATIONучастникBE359 064 €
VILABS (CY) LTDучастникCY331 250 €
NETCOMPANY S.A.участникLU325 000 €
MEDIZINISCHE UNIVERSITAT GRAZучастникAT312 875 €
TECREANDO B.V.участникNL311 112 €
UAB TERAGLOBUSучастникLT306 875 €
ARTHUR'S LEGAL BVучастникNL301 250 €
AINIGMA TECHNOLOGIESучастникBE272 500 €
CSI CENTER FOR SOCIAL INNOVATION LTDучастникCY238 125 €
KLINICKA BOLNICA DUBRAVAучастникHR226 562 €
D.TSAKALIDIS-G.DOMALIS OEучастникEL220 000 €
CSCY COMPUTER SOLUTIONS CYPRUS LTDучастникCY215 000 €
SMARTSOL SIAучастникLV210 625 €
I2GROW INNOVATION TO GROW SRLучастникIT203 125 €
BLOKS ZDRAVNI I SOTSIALNI GRIZHI EOODучастникBG54 688 €
REGION MIDTJYLLANDучастникDK9 040 €
SPHYNX TECHNOLOGY SOLUTIONS AGасоцииран партньорCH
CAMBRIDGE MEDICAL ACADEMY LTDасоцииран партньорUK
MARTEL GMBHасоцииран партньорCH

Описание

DIOPTRA aims to introduce a front-line screening tool that will consider risk factors and protein biomarkers for pinpointing individuals at a high risk for colorectal cancer (CRC) incidence. Tissue & blood samples will be examined towards a discriminative set of prognostic proteins that are detectable via standard bloodwork and can indicate a need for further evaluation (i.e. colonoscopy). Other data (e.g. medical, behavioural) will also be considered as potential risk factors. Artificial intelligence (AI) will be leveraged for assessing prognostic power, while personalised behavioural change will be promoted based on modifiable risk factors. Given the low citizen participation on CRC screening across EU, DIOPTRA seeks to broaden the evaluated population, boosting participation rates and bypassing age screening thresholds. This action is part of the Cancer Mission cluster of projects on ‘Prevention, including Screening’.

Официални данни · CORDIS · синхронизирано 17.10.2026 10:16 · официален запис · Лиценз: © European Union, CC BY 4.0 (Commission reuse policy).